Cholesterol drug setback casts doubt over multibillion-dollar race

The recent setback for Novartis' cholesterol drug has significant implications for the pharmaceutical industry, particularly for companies like Amgen and Eli Lilly that are also invested in developing treatments to lower Lp(a) levels. Lp(a) is a type of cholesterol that has been linked to an increased risk of heart attacks and strokes, and the potential market for effective treatments is substantial. The failure of Novartis' drug raises questions about the viability of this approach and puts pressure on other companies to demonstrate the efficacy of their own treatments.

The stakes are high in this race, with potential revenues estimated in the billions of dollars. Amgen and Eli Lilly are among the companies with promising candidates in development, and their success or failure will be closely watched by investors and industry analysts. The challenge for these companies is to demonstrate not only that their treatments can lower Lp(a) levels, but also that this reduction translates into fewer heart attacks and strokes. This requires large and complex clinical trials, which are costly and time-consuming.

As the competition in this space continues to unfold, industry observers will be watching closely for updates on the progress of Amgen and Eli Lilly's candidates. Key milestones to watch include the release of clinical trial data, regulatory approvals, and ultimately, the commercial launch of any successful treatments. The outcome of this race will have significant implications for the pharmaceutical industry and for public health, and will be closely followed by trade publications and industry analysts.

Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.